Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Patients with early-stage EGFR-positive non-small-cell lung cancer have a high risk of recurrence within 2 years of resection but individual factors may help predict outcomes
Women receiving anthracycline-based treatment for nonmetastatic breast cancer could benefit from the use of cardioprotective agents such as bisoprolol and ramipril
Two years of aromatase inhibitor therapy after initial endocrine treatment provides similar survival outcomes to a 5-year course while reducing the risk of treatment-related bone fracture
Two years of zoledronate therapy may be adequate for women who undergo surgery for node-positive or high-risk node-negative early breast cancer
A 12-week de-escalated neoadjuvant regimen has achieved high survival rates for HER2-positive, HR-negative early breast cancer patients
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
